Takeda Pharmaceutical Co Ltd v. Annora Pharma Pvt Ltd

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Takeda Pharmaceutical Company Limited (Japan)
  • Defendant: Annora Pharma Private Limited (India)
  • Plaintiff's Counsel: Saul Ewing LLP
• Case Identification: 2:26-cv-09729, D.N.J., 07/31/2026
• Venue Allegations: Plaintiff alleges venue is proper in the District of New Jersey because Defendant conducts business in the district, the district is a likely destination for the accused generic drug product, and Defendant has previously consented to personal jurisdiction in the district in prior patent litigation.
• Core Dispute: Plaintiff alleges that Defendant's submission of an Abbreviated New Drug Application (ANDA) for a generic version of Plaintiff's LIVTENCITY® drug constitutes an act of infringement of a patent covering compositions of the active ingredient, maribavir.
• Technical Context: The technology relates to pharmaceutical compositions of maribavir, an antiviral drug used to treat cytomegalovirus (CMV) infections, which are a significant risk for transplant recipients.
• Key Procedural History: This is a Hatch-Waxman action initiated under 35 U.S.C. § 271(e)(2) in response to Defendant's submission of ANDA No. 221113 containing a Paragraph IV certification. The patent-in-suit is listed in the U.S. Food and Drug Administration's "Orange Book" for the LIVTENCITY® product.

Case Timeline

Date	Event
2022-10-12	U.S. Patent No. 12,527,771 Priority Date
2026-01-20	U.S. Patent No. 12,527,771 Issues
2026-06-26	Defendant sends Paragraph IV Notice Letter to Plaintiff
2026-07-31	Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 12,527,771 - "Viral Inhibitors, The Synthesis Thereof, and Intermediates Thereto"

• Patent Identification: U.S. Patent No. 12,527,771 ("the '771 Patent"), titled "Viral Inhibitors, The Synthesis Thereof, and Intermediates Thereto," issued on January 20, 2026.

The Invention Explained

• Problem Addressed: The patent's background section describes prior methods for synthesizing the antiviral drug maribavir as suffering from low overall yields and the production of undesirable byproducts, which impacts commercial-scale manufacturing efficiency and cost '771 Patent, col. 2:54-65 '771 Patent, col. 4:55-59
• The Patented Solution: The patent claims to solve this problem by disclosing compositions of maribavir that are defined by the presence of specific, low-level impurities generated during synthesis '771 Patent, abstract '771 Patent, col. 8:1-13 By controlling for these impurities, the invention purports to represent a more efficient and purer manufacturing outcome. Claim 1, for example, claims a composition of maribavir that includes one or more of four specified compounds (impurities) at concentrations of 0.1% w/w or less '771 Patent, claim 1
• Technical Importance: Achieving high-purity active pharmaceutical ingredients with a consistent and minimal impurity profile is critical for drug safety, regulatory approval, and cost-effective manufacturing at a commercial scale.

Key Claims at a Glance

• The complaint alleges infringement of "one or more claims" without specifying which ones Compl. ¶29 Independent claim 1 is representative of the patent's composition claims.
• Independent Claim 1 requires:
  • A composition of maribavir;
  • And one or more compounds selected from the group consisting of Compound 9, Compound 10, Compound 11, and Compound 12;
  • Wherein Compound 9 is present in an amount of 0.1% w/w or less relative to maribavir;
  • Wherein Compound 10 is present in an amount of 0.1% w/w or less relative to maribavir;
  • Wherein Compound 11 is present in an amount of 0.1% w/w or less relative to maribavir; and
  • Wherein Compound 12 is present in an amount of 0.1% w/w or less relative to maribavir.
• The complaint does not explicitly reserve the right to assert dependent claims, but makes a general allegation of infringement of "one or more claims" Compl. ¶29

III. The Accused Instrumentality

Product Identification

• The accused instrumentality is Defendant Annora's Abbreviated New Drug Application (ANDA) No. 221113, which seeks FDA approval for "maribavir tablets, 200 mg" ("Annora's ANDA Product") Compl. ¶21

Functionality and Market Context

• Annora's ANDA Product is intended to be a generic version of Takeda's LIVTENCITY®, an antiviral drug indicated for the treatment of post-transplant cytomegalovirus (CMV) infection/disease Compl. ¶5 Compl. ¶25
• The complaint alleges that this action arises from Annora's submission of the ANDA seeking approval to manufacture and sell its generic version prior to the expiration of the patent-in-suit Compl. ¶1

No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

The complaint provides a generalized allegation of infringement without a detailed claim chart or element-by-element analysis. The following table summarizes the infringement theory as implied by the complaint's allegations.

'771 Patent Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A composition of maribavir	The complaint alleges that Annora's ANDA Product is a 200 mg maribavir tablet intended to be a generic version of LIVTENCITY®.	¶21; ¶25	col. 1:40-52
and one or more compounds selected from the group consisting of Compound 9, Compound 10, Compound 11, and Compound 12... wherein [each specified compound] is present in an amount of 0.1% w/w or less relative to maribavir.	The complaint alleges that Annora's ANDA submission constitutes an act of infringement, which implies that the product described therein will meet all limitations of at least one claim, including the presence of the specified impurities at the claimed levels.	¶27; ¶29	col. 15:5-39; col. 15:40-65

• Identified Points of Contention:
  • Evidentiary Question: The central dispute will likely be factual and evidentiary: does Annora's ANDA product, when manufactured according to the process described in its ANDA, contain any of the specific impurities (Compounds 9, 10, 11, or 12) as required by claim 1? If so, are they present at or below the claimed 0.1% w/w threshold?
  • Technical Question: The case may turn into a dispute between analytical chemists regarding the methods used to detect and quantify these trace impurities and whether the levels fall within the claimed ranges.

V. Key Claim Terms for Construction

The complaint does not provide sufficient detail for a definitive analysis of claim construction disputes. However, based on the nature of the claims, the following term may be central to the infringement analysis.

• The Term: "in an amount of 0.1% w/w or less"
• Context and Importance: This quantitative limitation is the core of the claimed invention. Infringement hinges entirely on whether the accused product contains specific impurities within this precise, low-level range. Practitioners may focus on this term because the case will depend on the sensitivity and margin of error of the analytical techniques used to measure these amounts.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The patent consistently uses the phrase "less than" a certain percentage (e.g., "less than 0.10% (w/w HPLC)") which could support an argument that any detectable amount below the 0.1% ceiling is infringing '771 Patent, col. 8:65-67
  • Evidence for a Narrower Interpretation: The patent also discloses compositions where an impurity is "not detectable by HPLC" '771 Patent, col. 9:9-10 A defendant might argue that its product contains non-detectable levels of the specified impurities, raising the question of whether "not detectable" is distinct from, or a species of, "0.1% w/w or less," and how the limits of detection for the analytical methods employed should be treated.

VI. Other Allegations

• Indirect Infringement: The complaint makes conclusory allegations of induced infringement under 35 U.S.C. § 271(b) and contributory infringement under 35 U.S.C. § 271(c), based on Annora's alleged intent for its product to be used in an infringing manner upon FDA approval Compl. ¶¶30-31
• Willful Infringement: The complaint alleges that Annora has had knowledge of the '771 Patent since at least the date of its Paragraph IV Certification, which may serve as a basis for a willfulness claim Compl. ¶32 Plaintiff also seeks a finding that the case is "exceptional" to recover attorneys' fees under 35 U.S.C. § 285 Compl. ¶34

VII. Analyst's Conclusion: Key Questions for the Case

This case will likely depend on the answers to two central questions for the court:

1. A core question will be one of factual evidence: Can Takeda demonstrate through analytical chemistry that Annora's generic maribavir product, as specified in its ANDA, will inevitably contain one or more of the specific chemical impurities laid out in the '771 Patent's claims, and that these impurities fall within the claimed low-level quantitative limits?

2. A dispositive issue will be one of patent validity: Will Annora be able to prove, by clear and convincing evidence, that the '771 Patent's claims are invalid, for instance, by arguing that achieving the claimed impurity profile would have been obvious to a person of ordinary skill in the art of pharmaceutical chemistry tasked with synthesizing maribavir?